Pancreatic cancer: clinical trials in Switzerland
13 open trials in Switzerland for pancreatic cancer and 17 open trials accepting several types of cancer, according to ClinicalTrials.gov, updated on October 22, 2026.
These results are indicative and do not replace medical advice — discuss them with your doctor.
Open trials
- A 2-part Phase 1/2 Open-label Trial on ODM-212
NCT07563738RecruitingPhase 1 · Phase 2
In Switzerland: Bellinzona
- A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)
NCT06428409RecruitingPhase 1 · Phase 2
In Switzerland: Bellinzona, Geneva
- A Beta-only IL-2 ImmunoTherapY Study
NCT05086692RecruitingPhase 1 · Phase 2
In Switzerland: Zurich
- A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma
NCT07522073RecruitingPhase 3
In Switzerland: Basel, Bern, Geneva, Lausanne, Zurich
- ToPanc Trial: Survival After Total Versus Partial Pancreaticoduodenectomy for Adenocarcinoma of the Pancreatic Head, Distal Cholangiocarcinoma, and Ampullary Cancer
NCT06801899Recruiting
In Switzerland: Aarau, Baden, Basel, Bern, Geneva, St. Gallen, Zurich
- Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
NCT06562192RecruitingPhase 1
In Switzerland: Geneva, Lausanne
- Structured Case-Finding for Pancreatic Ductal Adenocarcinoma in Swiss Primary Care: A Feasibility Study
NCT07723781Not yet recruiting
In Switzerland: Zurich
- FAPI PET Imaging - An Exploratory Study
NCT07705074Not yet recruitingPhase 1 · Phase 2
In Switzerland: Baden, Geneva, Genolier, Lucerne, Zurich
- A Study of Sigvotatug Vedotin in Advanced Solid Tumors
NCT04389632RecruitingPhase 1
In Switzerland: Chur, Lausanne
- Impact of GLP-1 Receptor Agonists on Patients With IPMN
NCT07014709Not yet recruiting
In Switzerland: Villars-sur-Glâne
- 68Ga-FAPI-46 in Staging of Pancreatic Adenocarcinoma
NCT06911021Not yet recruiting
In Switzerland: Lausanne
- Microbiota and Pancreatic Cancer Cachexia
NCT05606523Recruiting
In Switzerland: Geneva
- Stereotactic Body Radiotherapy in Patients With Rare Oligometastatic Cancers (OligoRARE)
NCT04498767Recruiting
In Switzerland: Bern, Zurich
Trials open to several types of cancer
These trials accept several types of cancer, perhaps yours: talk to your doctor about them.
- A Clinical Trial of MK-2010 With Sacituzumab Tirumotecan (Sac-TMT) in Participants With Solid Tumors (MK-2010)
NCT07785609RecruitingPhase 2
In Switzerland: Bellinzona, St. Gallen
- A Clinical Trial of MK-2010 Alone and With Other Treatments in Participants With Advanced Solid Tumors (MK-2010-002)
NCT07793942Not yet recruitingPhase 2
In Switzerland: Lausanne, St. Gallen
- A Study of Calderasib (MK-1084) in KRAS Mutant Advanced Solid Tumors (MK-1084-001)
NCT05067283RecruitingPhase 1
In Switzerland: Bellinzona, St. Gallen
- Anti-GD2 ADC M3554 in Advanced Solid Tumors
NCT06641908RecruitingPhase 1
In Switzerland: Zurich
- A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
NCT06760819RecruitingPhase 2
In Switzerland: Bern, Geneva, Zurich
- Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
NCT05176483RecruitingPhase 1
In Switzerland: St. Gallen, Winterthur
- Safety and Early Signs of Efficacy of IL12-L19L19.
NCT04471987RecruitingPhase 1
In Switzerland: Basel, Bellinzona, Bern, Geneva
- A Nutrition and Exercise Program With Olanzapine Compared to Olanzapine Alone: A Trial in Patients With Advanced Tumors
NCT07722806Not yet recruitingPhase 2
In Switzerland: Winterthur
- A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors
NCT05836324RecruitingPhase 1
In Switzerland: Bellinzona, Lausanne, St. Gallen
- A Rollover Study Evaluating Sotorasib With or Without Panitumumab in Participants With KRAS p.G12C Mutation
NCT07172919RecruitingPhase 2
In Switzerland: Basel
- A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
NCT05384626RecruitingPhase 1 · Phase 2
In Switzerland: Bellinzona, Lucerne
- A Phase 1/2, First-in-Human Study On ODM-212 In Subjects With Selected Advanced Solid Tumours
NCT06725758RecruitingPhase 1 · Phase 2
In Switzerland: Bellinzona
- First in Human Study of T3P-Y058-739 (T3P)
NCT05120596RecruitingPhase 1 · Phase 2
In Switzerland: Bern, Lausanne, Zurich
- Tumor Molecular Profiling in Early Phase Clinical Trials
NCT04510766Recruiting
In Switzerland: Bellinzona
- A Study to Evaluate Tovorafenib in Pediatric and Young Adult Participants With Relapsed or Progressive Low-Grade Glioma and Advance Solid Tumors
NCT04775485RecruitingPhase 2
In Switzerland: Zurich
- Safety and Modulation of Adaptive Immunity by Iscador® Qu Viscum Album Extract in Patients With Advanced, Recurrent or Metastatic Cancers Treated With Immune Checkpoint Inhibitors
NCT06408688RecruitingPhase 4
In Switzerland: Baden, Basel, Liestal, St. Gallen
- INFORM2 Study Uses Nivolumab and Entinostat in Children and Adolescents With High-risk Refractory Malignancies
NCT03838042RecruitingPhase 1 · Phase 2
In Switzerland: Zurich